Discounted Cash Flow (DCF) Analysis Unlevered
Inspire Medical Systems, Inc. (INSP)
$309.69
+7.46 (+2.47%)
All numbers are in Millions, Currency in USD
Operating Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 50.59 | 82.05 | 115.38 | 233.39 | 392.94 | 661.56 | 1,113.80 | 1,875.20 | 3,157.09 | 5,315.28 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
EBITDA | -18.13 | -30.59 | -54.13 | -38.62 | -134.17 | -225.89 | -380.31 | -640.29 | -1,078 | -1,814.92 |
EBITDA (%) | ||||||||||
EBIT | -18.52 | -31.08 | -54.97 | -39.84 | -136.03 | -230 | -387.22 | -651.93 | -1,097.59 | -1,847.91 |
EBIT (%) | ||||||||||
Depreciation | 0.39 | 0.50 | 0.84 | 1.22 | 1.86 | 4.11 | 6.91 | 11.64 | 19.59 | 32.98 |
Depreciation (%) |
Balance Sheet Data
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Total Cash | 188.21 | 149.47 | 234.36 | 214.47 | 451.41 | 1,275.57 | 2,147.55 | 3,615.61 | 6,087.25 | 10,248.51 |
---|---|---|---|---|---|---|---|---|---|---|
Total Cash (%) | ||||||||||
Account Receivables | 6.67 | 13.13 | 25.06 | 34.18 | 61.23 | 107.34 | 180.72 | 304.27 | 512.27 | 862.45 |
Account Receivables (%) | ||||||||||
Inventories | 2.67 | 5.83 | 8.48 | 17.23 | 11.89 | 39.88 | 67.14 | 113.03 | 190.30 | 320.39 |
Inventories (%) | ||||||||||
Accounts Payable | 3.43 | 4.46 | 7.21 | 11.66 | 26.85 | 40.08 | 67.47 | 113.60 | 191.26 | 322 |
Accounts Payable (%) | ||||||||||
Capital Expenditure | -0.25 | -2.74 | -2.45 | -4.67 | -9.10 | -13.59 | -22.89 | -38.54 | -64.88 | -109.23 |
Capital Expenditure (%) |
Weighted Average Cost Of Capital
Share price | $ 309.69 |
---|---|
Beta | 1.435 |
Diluted Shares Outstanding | 28.07 |
Cost of Debt | |
Tax Rate | -0.12 |
After-tax Cost of Debt | 5.00% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 10.464 |
Total Debt | 7.54 |
Total Equity | 8,693.54 |
Total Capital | 8,701.08 |
Debt Weighting | 0.09 |
Equity Weighting | 99.91 |
Wacc |
Build Up Free Cash
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 50.59 | 82.05 | 115.38 | 233.39 | 392.94 | 661.56 | 1,113.80 | 1,875.20 | 3,157.09 | 5,315.28 |
---|---|---|---|---|---|---|---|---|---|---|
EBITDA | -18.13 | -30.59 | -54.13 | -38.62 | -134.17 | -225.89 | -380.31 | -640.29 | -1,078 | -1,814.92 |
EBIT | -18.52 | -31.08 | -54.97 | -39.84 | -136.03 | -230 | -387.22 | -651.93 | -1,097.59 | -1,847.91 |
Tax Rate | 0.00% | -0.12% | -0.20% | -0.17% | -0.12% | -0.12% | -0.12% | -0.12% | -0.12% | -0.12% |
EBIAT | -18.52 | -31.12 | -55.08 | -39.91 | -136.20 | -230.28 | -387.70 | -652.74 | -1,098.95 | -1,850.19 |
Depreciation | 0.39 | 0.50 | 0.84 | 1.22 | 1.86 | 4.11 | 6.91 | 11.64 | 19.59 | 32.98 |
Accounts Receivable | - | -6.46 | -11.93 | -9.12 | -27.05 | -46.12 | -73.38 | -123.54 | -208 | -350.19 |
Inventories | - | -3.17 | -2.64 | -8.75 | 5.34 | -27.99 | -27.26 | -45.89 | -77.27 | -130.09 |
Accounts Payable | - | 1.03 | 2.75 | 4.46 | 15.18 | 13.23 | 27.40 | 46.13 | 77.66 | 130.74 |
Capital Expenditure | -0.25 | -2.74 | -2.46 | -4.67 | -9.10 | -13.59 | -22.89 | -38.54 | -64.88 | -109.23 |
UFCF | -18.38 | -41.97 | -68.52 | -56.77 | -149.96 | -300.65 | -476.92 | -802.95 | -1,351.84 | -2,275.96 |
WACC | ||||||||||
PV UFCF | -149.96 | -272.18 | -390.87 | -595.76 | -908.04 | -1,384.01 | ||||
SUM PV UFCF | -3,550.86 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 10.46 |
Free cash flow (t + 1) | -2,321.48 |
Terminal Value | -27,440.67 |
Present Value of Terminal Value | -16,686.66 |
Intrinsic Value
Enterprise Value | -20,237.53 |
---|---|
Net Debt | -434.06 |
Equity Value | -19,803.47 |
Shares Outstanding | 28.07 |
Equity Value Per Share | -705.46 |